


Great Point Partners | Private Equity and Public Equity for Growing Health Care Companies – CEO Advisory Board – Bernhard Hampl, Ph.D.

























Skip Navigation





About Great Point Partners
For Entrepreneurs
For Intermediaries
Team
Portfolio
News
Careers
Contacts





CEO Advisory Board





Managing Directors
Principals /Senior Vice Presidents
Vice Presidents / Senior Associates
Associates / Analysts
Finance / Administration/ Investor Relations
CEO Advisory Board


Board Members

Bernhard Hampl, Ph.D.
Darren Head
Walter Herlihy, Ph.D.
Wayne Langlois
Martin LeBlanc
Robert Thomas
Donald Tomasso








					Bernhard Hampl, Ph.D.
				

					Board Member
                    Email: Dr. Bernhard Hampl


                    Dr. Hampl joined Great Point Partners’ Advisory Board in 2011 and is Co-Chairman of the Board of Directors of our portfolio companies Cytovance Biologics and Softbox Systems.  Dr. Hampl is President of BKH Pharma-Services, LLC and currently on the Board of Chenwerth Inc., a leading Active Pharmaceutical Ingredient ("API") provider to the pharmaceutical industry. Previously, Dr. Hampl was Executive Chairman of the Board of APP / Fresenius Kabi U.S. from 2009 to 2012. He is also a minority investor in several start-up pharmaceutical companies.
				

					Prior to that, Dr. Hampl was CEO of Eon Labs from 1996 to 2005 until the acquisition by Novartis at which time he became the CEO of the Sandoz US-division of Novartis. During the period he was CEO of Eon, its revenue grew from $20 million to $435 million.
				

					Dr. Hampl earned a Ph.D. in Pharmaceutical Chemistry from the Ludwig Maximilian University of Munich, Germany, School of Chemistry and Pharmacy.
				

					CEO Experience

Sandoz US-division of Novartis – biosimilar, biologic and generic pharmaceuticals
Eon Labs – specialty pharmaceuticals





Previous Profile
Next Profile









				©

				

				Great Point Partners

Site Map
Home
News
Legal Disclosure
Investor Portal




Search
























































 



Bernhard Hampl, Ph.D. Elected to Serve as Executive Chairman of the Board of Directors of Fresenius Kabi Pharmaceuticals Holding, Inc. | Business Wire


























































Bernhard Hampl, Ph.D. Elected to Serve as Executive Chairman of the 
      Board of Directors of Fresenius Kabi Pharmaceuticals Holding, Inc.






November 02, 2009 07:47 PM Eastern Standard Time



SCHAUMBURG, Ill.--(BUSINESS WIRE)--Fresenius Kabi Pharmaceuticals Holding, Inc., (NASDAQ: APCVZ), which 
      acquired APP Pharmaceuticals, Inc., September 10, 2008, today announced 
      the election of Bernhard Hampl, Ph.D. to its Board of Directors 
      effective November 1, 2009. Dr. Hampl, also named as Executive Chairman 
      of the Board, succeeds current Chairman Dr. Ulf M. Schneider. Dr. 
      Schneider will continue to serve on the Board of Directors and as a 
      member of the Audit Committee.
    


      “Dr. Hampl is one of the most experienced and well-respected leaders in 
      the generic pharmaceutical industry. His addition to the Board both 
      strengthens and broadens the depth of our industry expertise,” said Dr. 
      Schneider. “I am confident that Dr. Hampl is the right person to serve 
      as Executive Chairman and know that he has the strategic and operational 
      leadership experience that will allow us to capitalize on the 
      opportunities before us."
    

      "I have been fortunate to have worked extensively in the generic 
      pharmaceutical field and have witnessed many changes within our 
      industry. I am pleased to be joining the Board of Fresenius Kabi 
      Pharmaceuticals Holding and look forward to using my experience to 
      expand APP’s pipeline, while exploring new opportunities that will 
      position it for future growth," said Dr. Hampl.
    

      Dr. Hampl also serves as a member of the Board of Directors of 
      ChemWerth, Inc., a private corporation, and as an advisor to Advent 
      International Corporation, Farmhispania and Guidepoint Global.
    

      During his notable career, Dr. Hampl worked for 15 years for Cyanamid 
      GmbH and its business units, Lederle and Durachemie GmbH, where he held 
      positions as Director, Research and Development, Technical Director and 
      Plant Director. In 1995, Dr. Hampl joined Hexal AG, a leading 
      manufacturer and marketer of generic pharmaceuticals in Germany, and led 
      business development opportunities in the U.S. generics market. In 
      October 1995, Hexal acquired 50 percent of Eon Labs, Inc., and 100 
      percent ownership in 2000. During this time, Dr. Hampl served as 
      President and CEO. In July 2005, Sandoz, Inc., a division of Novartis 
      AG, completed its merger with Eon Labs and Dr. Hampl became the 
      President and Chief Executive Officer of Sandoz, Inc., the U.S. 
      operating unit of Sandoz. He resigned from Sandoz effective September 
      30, 2008. While CEO of Sandoz, Dr. Hampl also served as a member of the 
      Executive Board of the Generic Pharmaceutical Association. He received 
      his Ph.D. in pharmaceutical chemistry from Ludwig-Maximillians 
      University in Munich, Germany.
    

About APP Pharmaceuticals, Inc.


      APP Pharmaceuticals, Inc. is a fully-integrated pharmaceutical company 
      that develops, manufactures and markets injectable pharmaceutical 
      products with a primary focus on the oncology, anti-infective, 
      anesthetic/analgesic and critical care markets. The company offers one 
      of the most comprehensive product portfolios used in hospitals, 
      long-term care facilities, alternate care sites and clinics within North 
      America and manufactures a comprehensive range of dosage formulations. 
      Fresenius Kabi Pharmaceuticals Holding, Inc., a wholly owned subsidiary 
      of Fresenius Kabi AG, acquired APP Pharmaceuticals, Inc. on September 
      10, 2008. For more information about APP Pharmaceuticals, Inc., please 
      visit the company’s Web site at www.APPpharma.com.
    

About Fresenius Kabi AG


      Fresenius Kabi AG is the leader in infusion therapy and clinical 
      nutrition in Europe and in its most important countries of Latin America 
      and Asia Pacific. Fresenius Kabi’s core product range includes infusion 
      solutions for fluid substitution, blood volume expansion, I.V. drugs and 
      parenteral nutrition, as well as products for enteral nutrition. 
      Furthermore, the company provides concepts for ambulatory health care 
      and is focused on managing and providing home therapies. With the 
      philosophy “Caring for life” and a comprehensive product portfolio, the 
      company aims at improving the quality of life of patients all over the 
      world. In 2008, Fresenius Kabi achieved sales of EUR 2,495 million and 
      an operating profit of EUR 443 million. For more information visit the 
      company’s Web site at www.fresenius-kabi.com. 
      Fresenius Kabi AG is a 100% subsidiary of Fresenius SE.
    

About Fresenius SE


      Fresenius SE is a health care group with international operations, 
      providing products and services for dialysis, hospital and outpatient 
      medical care. In 2008, group sales were approximately EUR 12.3 billion. 
      On June 30, 2009 the Fresenius Group had 127,692 employees worldwide. 
      For more information visit the company’s Web site at www.fresenius.com.
    

Forward-Looking Statement


      The statements contained in this news release that are not purely 
      historical are forward-looking statements within the meaning of Section 
      21E of the Securities Exchange Act of 1934, as amended. Forward-looking 
      statements in this news release include statements regarding our 
      expectations, beliefs, hopes, goals, intentions, initiatives or 
      strategies, including statements regarding the demand, supply and 
      distribution of our products. Because these forward-looking statements 
      involve risks and uncertainties, there are important factors that could 
      cause actual results to differ materially from those in the 
      forward-looking statements. These factors include, but are not limited 
      to, the availability and pricing of ingredients used in the manufacture 
      of pharmaceutical products and the ability to successfully manufacture 
      products in a time-sensitive and cost effective manner. Additional 
      relevant information concerning risks can be found in the Fresenius Kabi 
      Pharmaceuticals Holding, Inc. 10-K for the fiscal year ending December 
      31, 2008 and other documents the company has filed with the Securities 
      and Exchange Commission.
    

      The information contained in this news release is as of the date of this 
      release. Fresenius Kabi Pharmaceuticals Holding, Inc. does not assume 
      any obligation to update or revise these forward-looking statements to 
      conform the statement to actual results, new information, developments 
      or changes in the Company’s expectations.
    


Contacts

APP ContactAPP Pharmaceuticals, Inc.Debra Lynn RossDirector, 
      Corporate Communications847-969-8026dross@apppharma.comorInvestor 
      InquiriesHill & KnowltonChristine Cassiano310-633-9495christine.cassiano@hillandknowlton.com













Contacts

APP ContactAPP Pharmaceuticals, Inc.Debra Lynn RossDirector, 
      Corporate Communications847-969-8026dross@apppharma.comorInvestor 
      InquiriesHill & KnowltonChristine Cassiano310-633-9495christine.cassiano@hillandknowlton.com







 
 

 






Search




Advanced News Search

Advanced News Search













Log In
Sign Up















Insider Trading - Hampl Bernard Dr - Form 4 SEC Filings












Home |
Archives |
Products |
About |
Contact |
FAQ |



New User?
Sign Up | 
Sign In









Form 4 Filings


Insider Buys


Significant Buys


Penny StocksInsider Buying


Insider Sales




Insider Buy Sell Ratios


Stock Options


Insider TradingStock Screener


Insider TradingGraph View


Insider Watch





Sec Filings Insider Trading - Hampl Bernard Dr





Select Time period: 
1 Month
2 Months
3 Months
6 Months
1 Year
2 Years
3 Years
4 Years
All Data
 

     



google

   



yahoo!



Send this page to:  

Blog
  



Digg

  



Reddit

  



Facebook

  



Stumble

  



del.icio.us








Enter Stock Ticker Symbol or Cik:




Cik Lookup...






Search By Company or Insider Name:







"Insiders might sell their shares for any number of reasons, but they buy them for only one:
they think the price will rise"
- Peter Lynch ==>>

What is insider trading>>



Email a friend >>...







Historical filings delayed by 6 months. New user?
Sign Up for real time data.
Existing user?
Sign In

Stock options: Exercise, Award, Grant, Conversion



TransactionDate
ReportedDate
ExercisableExpiration
Company
Symnbol
InsiderRelationship
SharesTraded
ConversionPrice
SharesOwned
Filing




2016-10-27Option Award
2016-10-314:05 pm
N/AN/A
Cambrex Corp
CBM
Hampl Bernard DrDirector
260
$0
316(Direct)
View


2016-10-27Option Award
2016-10-314:05 pm
2017-04-272023-10-27
Cambrex Corp
CBM
Hampl Bernard DrDirector
316
$41.05
316(Direct)
View









    © 2005-2017 SecForm4.Com All rights reserved.
    Archives:
    2017 2016 2015 2014 2013 2012 ... 
    Sun, 23 Jul 2017 19:00:24 -0500
  

    SEC is the U.S. Securities and Exchange Commission. EDGAR is a trademark of the SEC.
    SecForm4.Com is not affiliated with or approved by the U.S. Securities and Exchange Commission (SEC).
Terms of Use |
    Privacy Statement |
  










Bernhard Hampl Ph.D.: Executive Profile & Biography - Bloomberg









































  





















































































July 23, 2017 8:00 PM ET
Capital Markets

Company Overview of Advent International Corporation



SnapshotPeople 




OverviewBoard MembersCommittees



Executive Profile
Bernhard   Hampl Ph.D.Industry Advisor, Advent International CorporationAgeTotal Calculated CompensationThis person is connected to 4 Board Members in 4 different organizations across 9 different industries.See Board Relationships67--
Background

		Dr. Bernhard Hampl, Ph.D., serves as President of BKH Pharma-Services. Dr. Hampl is an Industry Advisor to Advent International Corporation. Dr. Hampl serves as an Advisor to Farmhispania and Guidepoint Global. He advises companies from the field of pharmaceuticals and biotechnology as well as investment companies. He is also a minority investor in several start-up pharmaceutical companies. He served as the Chief Executive Officer at Eon Labs, Inc. from October 1995 ... to 2005 and it's President since January 1996. During the period, he served as the Chief Executive Officer of Eon. He served as the Chief Executive Officer of the Sandoz US-Division and Head of Sandoz Operations - US Region at Novartis AG. He served as the Chief Executive Officer and President of Sandoz Inc. from July 2005 to 2008. He was responsible for all United States operations for Sandoz. He served on Hexal AG to evaluate the possibility of establishing a United States subsidiary from May 1995 to October 1995. During this time, he served as the President and Chief Executive Officer at Hexal AG. He served as Department Head of Research and Development of Cyanamid GmbH and its business unit Lederle and Durachemie GmbH, where he was responsible for research and development activities in Germany for the medical, agricultural and veterinary business of Cyanamid GmbH and from April 1980 to May 1995 as its Technical Director. He serves as an Executive Chairman of the Board of APP/Fresenius. He has been a Co-Chairman of the Board of Softbox Systems Ltd. since July 8, 2014. Dr. Hampl serves as a Member of the Board of Directors of ChemWerth Inc and UConn Ventures. Dr. Hampl has been a Director of Cambrex Corporation since October 27, 2016. He has been a Member of Chief Executive Officer Advisory Board at Great Point Partners, LLC since 2011. He serves as a Director of SiO2 Medical. He has been a Member of Advisory Board at Formycon AG since March 13, 2014. He served as Co-Chairman of the Board of Directors at Cytovance Biologics, Inc. He served as an Executive Chairman of Fresenius Kabi Pharmaceuticals Holding, Inc. from November, 2009 to February 17, 2011. He served as a Director of Fresenius Kabi Pharmaceuticals Holding, Inc. from November, 2009 to February 17, 2011. He served as a Member of the Board of Directors at the Generic Pharmaceutical Association, (GPhA). He has wide-ranging international experience. Dr. Hampl has over 30 years of experience in the pharmaceutical industry, leading companies competing within the generic and branded drug space. Dr. Hampl holds Bachelor Degree in Pharmaceutical Sciences and a Ph.D. in Pharmaceutical Chemistry from Ludwig Maximillian University of Munich, Germany, School of Pharmacy.Read Full Background




Corporate Headquarters
75 State StreetBoston, Massachusetts 02109United StatesPhone: 617-951-9400Fax: 617-951-0566
Board Members Memberships
Co-Chairman of the BoardSoftbox Systems Ltd.2016-PresentDirectorCambrex Corporation
Education
PhD Ludwig-Maximilians-Universität MünchenBachelor's Degree Ludwig-Maximilians-Universität München
Other Affiliations
Fresenius Kabi Pharmaceuticals Holding, Inc.Eon Labs, Inc.Cambrex CorporationNovartis AGLudwig-Maximilians-Universität MünchenGreat Point Partners, LLCAssociation for Accessible MedicinesSandoz International GmbHCytovance Biologics, Inc.Formycon AGSoftbox Systems Ltd.


Annual Compensation
				There is no Annual Compensation data available.
				Stocks Options
				There is no Stock Options data available.
				Total Compensation
				There is no Total Compensation data available.
			



Request Profile Update
















 












The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking 
	here.




Stock Quotes


Market data is delayed at least 15 minutes.







Company Lookup



COMPETITOR COMPENSATIONThere is no Competitor Compensation data available.










Sponsored Financial Commentaries

Sponsored Links






Browse Companies
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
 | 
0
1
2
3
4
5
6
7
8
9






Request Profile Update

						Only a company representative may request an update for the company profile. Documentation will be required.
					  
To contact Advent International Corporation, please visit .  Company data is provided by S&P Global Market Intelligence.  Please use this form to report any data issues.
					  


Information Missing - Please enter your information in the following field(s): 




Company Name

Your Name*

Your E-Mail Address*

Your Phone Number*

Type of Data*


Overview
Executives
Key developments
Similar companies
Transactions


Update Needed*

All data changes require verification from public sources.  Please include the correct value or values and a source where we can verify.


Cancel


Submit






Your requested update has been submitted
Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.


Close




























BERNARD DR  HAMPL - CEO, founder, businessman - profile

















directorpedia.net - List of CEOs, founders, board members and company directors











BERNARD DR  HAMPL
Check out list of companies and businesses related to BERNARD DR  HAMPL. Find out BERNARD DR  HAMPL address and contact details. View other people related to BERNARD DR  HAMPL - coworkers, colleagues, companions, etc.
Address:   

227-15 NORTH CONDUIT AVENUE  LAURELTON 11413 NY




Companies related to BERNARD DR  HAMPL
CIKCompany NamePositionCompany Address0000820081CAMBREX CORPDirector ONE MEADOWLANDS PLAZA  E. RUTHERFORD 070730001168061EON LABS INCPresident and CEO 787 SEVENTH AVE  NEW YORK 10019




BERNARD DR  HAMPL on the Web
Persons related to BERNARD DR  HAMPL - CAMBREX CORPNamePositionCityGupta  AnupVice President EAST RUTHERFORDLUKE M  BESHARExecutive Vice President EAST RUTHERFORDLUKE M  BESHAREVP & CFO EAST RUTHERFORDDAVID R  BETHUNEDirector EAST RUTHERFORDTHOMAS N  BIRDFormer Vice President EAST RUTHERFORDTHOMAS N  BIRDVP Corporate Development EAST RUTHERFORDRONNIE D  CARROLLVice President EAST RUTHERFORDRONNIE D  CARROLLVP & CTO EAST RUTHERFORDShawn  CavanaghEVP & COO EAST RUTHERFORDRobert J  CongiustiVice President EAST RUTHERFORDROSINA B  DIXONDirector ROSINA B  DIXONDirector EAST RUTHERFORDN DAVID  EANSOR EAST RUTHERFORDN DAVID  EANSORPresident Bioproducts EAST RUTHERFORDCLAES  GLASSELLDirector CONCORDLouis J.  GrabowskyDirector NEW YORKSALVATORE J  GUCCIONE SRExecutive Vice President EAST RUTHERFORDROY W  HALEYDirector EAST RUTHERFORDBERNARD DR  HAMPLDirector LAURELTONSamantha  HanleyVP, General Counsel EAST RUTHERFORDKATHRYN  HARRIGANDirector EAST RUTHERFORDKATHRYN  HARRIGANDirector EAST RUTHERFORDKATHRYN  HARRIGANDirector EAST RUTHERFORDKATHRYN  HARRIGANDirector EAST RUTHERFORDWilliam M.  HaskelSenior Vice President EAST RUTHERFORDWilliam M.  HaskelSenior Vice President EAST RUTHERFORDLEON J  HENDRIX JRDirector LEON J  HENDRIX JRDirector EAST RUTHERFORDLEON J  HENDRIX JRDirector EAST RUTHERFORDILAN  KAUFTHALDirector EAST RUTHERFORDTLAN  KAUFTHALDirector EAST RUTHERFORDSTEVEN M  KLOSKPresident & CEO EAST RUTHERFORDSTEVEN M  KLOSKPresident & CEO EAST RUTHERFORDWILLIAM B  KORBDirector EAST RUTHERFORDROBERT  LEBUHNDirector EAST RUTHERFORDJohn R  LeonePresident & CEO EAST RUTHERFORDJohn R  LeonePresident & CEO EAST RUTHERFORDJAMES A  MACKPresident, CEO & Chairman EAST RUTHERFORDAldo  MagniniManaging Director, Profarmaco EAST RUTHERFORDDANIEL R  MARSHAKVice President EAST RUTHERFORDDANIEL R  MARSHAKVP & CTO EAST RUTHERFORDJOHN R  MILLERDirector EAST RUTHERFORDJOHN R  MILLERDirector EAST RUTHERFORDGARY L  MOSSMANFormer EVP & COO EAST RUTHERFORDPAOLO  RUSSOLOPresident, Cambrex Profarmaco EAST RUTHERFORDPAOLO  RUSSOLOPresident Cambrex Profarmaco EAST RUTHERFORDPAOLO  RUSSOLO EAST RUTHERFORDGREGORY  SARGENEVP, Corporate Development EAST RUTHERFORDPETER E  THAUSER SRSenior Vice President EAST RUTHERFORDPETER E  THAUSER SRSVP Law Gen Counsel Corp Sec EAST RUTHERFORDPETER E  THAUSER SRSenior Vice President EAST RUTHERFORDPETER G  TOMBROSDirector EAST RUTHERFORDPETER G  TOMBROSDirector EAST RUTHERFORD, NJ  07073Tom George  VadakethExecutive Vice President & CFO EAST RUTHERFORDHOORN PETER  VAN EAST RUTHERFORDJAMES F  WINSCHEL JRDirector EAST RUTHERFORDShlomo  YanaiDirector EAST RUTHERFORDF. Michael  ZacharaVice President EAST RUTHERFORDPersons related to BERNARD DR  HAMPL - EON LABS INCNamePositionCityJEFFREY S  BAUERVice President, Business Dev. LAURELTONJEFFREY S  BAUERVP, Business Development LAURELTONJEFFREY S  BAUERV.P., Business Development LAKE SUCCESSFRANK F  BEELITZDirector LAURELTONFRANK F  BEELITZDirector LAURELTONFRANK F  BEELITZLAURELTONFRANK F  BEELITZDirector LAKE SUCCESSDR PRANAB  BHATTACHARYYAVP, Qual. Mgmt & Analyical Svs LAURELTONDR PRANAB  BHATTACHARYYAVP, Quality Mgmt & Anlytc Ser. LAKE SUCCESSSADIE  CIGANEKVP, Regulatory Affairs LAURELTONSADIE  CIGANEKV.P., Regulatory Affairs LAKE SUCCESSFERA FRANK J  DELLAVP, Sales and Marketing LAURELTONFERA FRANK J  DELLAVP, Sales and Marketing LAURELTONFERA FRANK J  DELLAV.P., Sales & Marketing LAKE SUCCESSWILLIAM B  EVERSGERDVP, Plant Facilities LAURELTONWILLIAM B  EVERSGERDVP, Plant Facilities LAURELTONWILLIAM B  EVERSGERDVice Pres., Plant Facilities LAKE SUCCESSDAVID H  GRANSEEController & Asst. Secretary LAURELTONDAVID H  GRANSEEController & Asst. Secretary LAURELTONDAVID H  GRANSEEController & Asst. Secretary LAURELTONDAVID H  GRANSEEController & Asst. Secretary LAKE SUCCESSBERNARD DR  HAMPLPresident and CEO LAURELTONBERNARD DR  HAMPLPresident and CEO LAURELTONBERNARD DR  HAMPLPresident and CEO LAURELTONBERNARD DR  HAMPLPresident & CEO LAKE SUCCESSWILLIAM F  HOLTVP, Fin.; Sec'y; Treas. & CFO LAURELTONWILLIAM F  HOLTVP, Fin.; Sec.; Treas. & CFO LAKE SUCCESSDOUGLAS M  KARPDirector LAURELTONDOUGLAS M  KARPDirector LAKE SUCCESSRATHNAM  KUMARVP, Manufacturing LAURELTONRATHNAM  KUMARVice President, Marketing LAKE SUCCESSAG  NOVARTISBASEL SWITZERLANDNOVARTIS CORPNEW YORKMARK R  PATTERSONDirector LAURELTONMARK R  PATTERSONDirector LAKE SUCCESSDR LEON  SHARGELVP, Biopharmaceutics LAURELTONDR LEON  SHARGELVP, Biopharmaceuticals LAKE SUCCESSNITIN V  SHETHVP, Research & Development LAURELTONTHOMAS DR  STRUNGMANNDirector 83607 HOLZKIRCHEN, GERMANYTHOMAS DR  STRUNGMANNDirector BERLINShashank  UpadhyeLAURELTONShashank  UpadhyeVice President and Counsel LAURELTONShashank  UpadhyeVP and General Counsel LAKE SUCCESS












 






   Bernhard Hampl | Sandoz Inc | ZoomInfo.com


 SECGems: Hampl Bernhard 







































  







			Data feeds now available
			Excel / CSV / Java / Python /etc 
Database
Learn more









  




  


  






























 Hampl Bernhard 
		     










 Info




 Ownership




 Filings
11













	 
	
	 EON LABS INC
	 
	  227-15 N CONDUIT AVE
	
	   LAURELTON, 
	   NY, 
	  
	
	  
		
		

			
			 
		
		
		
		 USA
		
	
	   7182768606    
	    

						        









Filing DateCurrent and former namesChanged on date




2017-05-01Hampl Bernhard


2003-07-31HAMPL BERNARD DR








Central Index Key (CIK)
0001254930










Ownership (Form 3,4,5)# Filings





 HAMPL BERNARD DR (0001254930) 


10











All related persons/companies# Filings





 CAMBREX CORP (0000820081) 


3




 EON LABS INC (0001168061) 


8




 HAMPL BERNARD DR (0001254930) 


12







 








db
 
 









































Access Denied

Access Denied
 
You don't have permission to access "http://health.usnews.com/doctors/ori-hampel-92102" on this server.
Reference #18.34360760.1500854427.484287



Access Denied

Access Denied
 
You don't have permission to access "http://health.usnews.com/doctors/ori-hampel-92102" on this server.
Reference #18.34360760.1500854427.484288


